Korean J Blood Transfus.
2024 Apr;35(1):44-47. 10.17945/kjbt.2024.35.1.4 4.
COVID-19 Convalescent Plasma Therapy in Korea
- Affiliations
-
- 1Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea
- 2Division of Blood Safety Surveillance, National Institute of Organ, Tissue and Blood Management, Ministry of Health and Welfare, Seoul, Korea
- 3Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
- KMID: 2555558
- DOI: http://doi.org/10.17945/kjbt.2024.35.1.4 4
Abstract
- A global effort was made to respond to COVID-19 using convalescent plasma therapy. The United States Food and Drug Administration Emergency Use Authorization facilitated rapid deployment, enabling the treatment of 94,287 patients by August 2020. The guidelines continuously evolved to emphasize the importance of a high titer plasma and specific immunocompromised patient groups. Korea has developed guidelines for treatment with convalescent plasma based on the successful treatment of two patients. By December 2023, convalescent plasma was collected from 67 donors at nine blood centers and transfused to 67 patients at 10 hospitals in Korea. The Association for the Advancement of Blood and Biotherapies recommendations, based on recent research, are believed to encompass the therapeutic effects of convalescent plasma therapy in COVID-19 patients. Korea initially considered convalescent plasma but experienced difficulties in development because of the switch to hyperimmune globulin and monoclonal antibodies. The insights gained from COVID-19 convalescent plasma treatment will be helpful in future pandemics caused by new infectious agents, underscoring the importance of domestic readiness for timely policy implementation.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Practical Considerations in Convalescent Plasma Therapy for Coronavirus Disease 2019
- Convalescent Plasma Therapy for Coronavirus Disease 2019
- Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia
- Convalescent plasma in COVID-19: renewed focus on the timing and effectiveness of an old therapy
- Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
